On an earnings call earlier this week, Pfizer CEO Ian Read said that the company will be returning to “business as normal” on its drug pricing in January, after having agreed to hold off on price increases earlier this year following pressure from the Trump administration.
On an earnings call earlier this week, Pfizer CEO Ian Read said that the company will be returning to “business as normal” on its drug pricing in January, after having agreed to hold off on price increases earlier this year following pressure from the Trump administration.
Drug pricing has been a key issue in the political arena leading up to the midterm elections next week. President Trump, together with HHS Secretary Alex Azar, have narrowed their focus to lowering drug prices for American patients through numerous actions and efforts, some of which were outlined in the American Patients First blueprint.
To underscore the efforts to address drug prices, Trump began to put pressure on pharmaceutical companies individually. Following a conversation between Read and Trump in July, Pfizer announced that it would hold off on a planned price increase. Pfizer was not the only company to halt price hikes; around the same time, Merck, Novartis, and Roche also agreed to hit pause on price increases for the rest of 2018.
“Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!” tweeted Trump at the time.
However, on the latest earnings call, Read signaled that the agreement to hold off on price hikes would end at the end of 2018, at which point the company will return to pricing based on the market. “We price to the marketplace, we price competitively,” said Read.
Of note, the administration is not relying solely on voluntary actions from pharmaceutical companies to lower drug prices. Last week, Trump unveiled a new plan that aims to reduce Medicare’s costs for prescription drugs where CMS could set its prices for some drugs, including biologics, based on the prices paid in other nations.
The plan was met with mixed responses from industry stakeholders. CMS is currently taking comments on the pricing model until Monday, December 31, 2018, after which it plans to issue a proposed rule in spring 2019.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.